We continue to see a deluge of data from government actuaries and pharmacy benefit managers (PBMs) showing a dramatic slowdown in medicine spending growth. Most recently, the IQVIA Institute for Human Data Science released a report today that provides additional evidence to support the conclusion that the competitive market for medicines in the United States holds down costs.
Here are four things you should know about the “2018 and Beyond: Outlook and Turning Points” report:
- Spending on medicines per person in the United States is projected to decline in 2018 and continue almost unchanged through 2022.
- Prices for brand medicines are projected to increase just 2 to 5 percent over the next five years after accounting for negotiated discounts and rebates, even as a robust pipeline of new medicines are expected to reach patients.
- U.S. brand medicine sales are expected to decrease by $105 billion between 2018 and 2022 due to expected competition from generics and biosimilars, with a $35 billion decline in brand sales in 2018 alone.
- Over the next five years, new forms of contracting are likely to expand. Nearly three times more outcomes-based contracts – innovative and flexible ways to pay for medicines that lower out-of-pocket costs and get patients access to the right treatments the first time – are expected to be announced.
Learn more at LetsTalkAboutCost.org.
Holly Campbell
Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines.
Holly Campbell
Critics repeat same, misleading narrative on potential “costs” of new medicines
Insurance data: PBM reform has no material impact on premiums
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
3 Takeaways from POLITICO’s Health Care Summit
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
When it comes to the future of innovation, the ball is in policymakers’ court
AARP’s latest misleading report
New report: Hospitals mark up medicine prices 500%
read more
Key considerations as Congress works towards PAHPA reauthorization
Insulin: Key Facts on Access & Affordability
4 key facts on medicine prices and spending
Three facts about health care spending
ICYMI: Cancer death rate continues to decline due to treatment advances
Novel medicines approved in 2022 offer increased treatment options for patients
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
Study finds hepatitis C cure saved Medicaid $15 billion
New data show how insurers and middlemen shift Rx costs onto patients
Busting 3 Myths About Copay Coupons
Making coupons count for patients at the pharmacy counter
By the Numbers: Patients lose when the government sets prices
Prescription drug prices are not fueling inflation
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
Report finds PBMs are increasingly restricting patient access to medicines
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
Annual projections from NHE compared to actual health care spending
What’s really happening when it comes to prescription drug costs
Analysis: States can help patients save nearly $1,000 annually on their medicines
New analysis confirms hospitals markup prices for oncology therapies
How standardized plans can improve patients’ access to medicines
Correcting the record: Putting medicine costs and spending in context
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
Government price setting leaves behind families counting on new medicines
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
Research and development continues long after a medicine is initially approved
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
New study finds more than half of brand medicine spending goes to the supply chain and others
New NHE data show the true picture of health care spending
3 things to know about the importance of post-approval research and development
Guest post: Congress should not put future innovation at risk
What is missing in the current drug pricing plan
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
In the current health care debate, Congress has lost sight of what matters to U.S. voters
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
New poll shows Americans reject Medicare negotiation once they learn more about the policy
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
What is Kaiser Family Foundation up to?
Recognizing Hepatitis R&D on World Hepatitis Day
New reports shed light on key facts about medicines and affordability
How strengthening the biosimilar marketplace benefits patients
New report demonstrates development of new medicines relies on private sector expertise and investment
New data from insurers show detriments of copay accumulator adjustment programs
West Virginia becomes the first state to lower patient costs by sharing the savings
Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter
Top five issues voters want addressed in the administration’s first 100 days
Insurers shift medicine costs to patients with severe chronic illnesses
The new Administration should reconsider a recent HHS rule that could negatively impact patient access and affordability
New insulin report highlights how incentives benefit middlemen, harm patients
New data show retail medicine prices fell in 2019
Fact Check: How hospitals continue to drive health care spending
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
Survey found insurance premiums grew faster than inflation in 2020
Study finds middlemen excluded nearly 850 medicines from formularies this year
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
New data show commercially insured patients face increasingly high cost sharing for brand medicines
Payers subject 80% of new RA and MS patients to utilization management restrictions
Study finds the pharmaceutical industry retains a smaller share of revenue than research-intensive industries
ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access
New rule makes it harder for patients to lower their out-of-pocket costs
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Retail medicine spending to remain stable share of overall health care spending through next decade
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
Addressing barriers that inhibit value-based contracts
Fact Check: HCCI analysis overstates medicine spending and prices
Cancer medicines cost twice as much at hospitals, study finds
Nearly 50% of brand medicine spending goes to the supply chain and others
New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
More evidence that medicine prices are growing at slowest rate in decades
The truth about the marketing and promotion of medicines
Survey shows out-of-pocket costs top health care concern for voters
Four reasons why the radical Pelosi Plan is the wrong approach
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
Three things to know about the Part D GAO report
Setting the record straight on international reference pricing
Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices
New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?
Study finds hospitals continue to mark up medicines up to 500% of their cost
Three reasons why the latest Rx Savings Solutions analysis is misleading
"If Washington isn’t careful, we might leave innovation behind"
How the rebate rule would help reduce patients’ out-of-pocket costs
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
New study finds hospitals continue to push patients to costlier outpatient settings
4 Things to know about the IQVIA “Medicine Use and Spending” report
Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”
Six policy solutions to help patients afford their insulin
PhRMA comments on OIG proposed rule to reform the rebate system
340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings
Five key facts about the market for insulins
OIG proposed rule could help strengthen the Part D market
Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer
The PBM story you haven’t heard: Hidden fees quadrupled in two years
OptumRX: Sharing rebates with patients is “worth it”
New data show how sharing negotiated discounts could save certain patients hundreds of dollars at the pharmacy counter
What you need to know about the new NHE health spending projections
New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis
New IQVIA data show medicine prices grew just 1.5 percent in 2018
Health Affairs study misses the mark on medicine costs
New government data show medicine price growth continues to decline
10 things you should know about medicine spending and costs
Six key facts about the market for insulins
Americans want to know more than just the list price of a medicine—and we’re answering their call
What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
New study finds some hospitals mark up medicine prices at least 700 percent
69 percent of patients abandon medicines when cost sharing is more than $250
New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs
Pass-through rebates do not violate non-interference clause but they do increase savings for seniors
Medicare Part D cliff ahead
Patients with a deductible have seen their out-of-pocket costs for brand medicines increase 50 percent since 2014
Part D cliff looms for seniors, as program stability could be in jeopardy
ICYMI: Analysis finds higher outpatient drug spending at 340B hospitals
Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually
New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
Event tomorrow: Making the biopharmaceutical supply chain work for patients
Spending on medicines grew less than one percent in 2017
Patients pay the price when hospitals mark up cancer medicines
Advance price notification: A transparency measure that fails patients
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
Video: How does the supply chain shape brand-name medicine prices?
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Copay coupons can help ease patients’ out-of-pocket costs
Oregon’s HB 4005 fails to deliver savings for patients
PhRMA launches new consumer-facing Let’s Talk About Cost website
NHE Data: Medicine spending grew just 1.3 percent in 2016
Video: What is a results-based contract?
Excerpts from testimony by PhRMA’s Lori Reilly
4 things to know about the QuintilesIMS drivers of medicine spending in the U.S. report
What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace
Video: PhRMA CEO discusses medicine costs with CNBC's Squawk Box
New PhRMA resources chock full of biopharma industry facts
New “Let’s Talk About Cost” campaign convenes national dialogue on medicine costs
New data put medicine costs and spending in context
In the OECD other health care services will be ten times prescription medicine spending growth over next decade
Medicines have significantly increased chances of cancer survival around the globe
Why won’t the insurance industry tell the truth about medicine costs?
4 Things to know about the QuintilesIMS Medicines Use and Spending in the U.S. report
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
How innovative medicines are benefiting countries across the globe
ICYMI: 3 new reports show dramatic slowdown in medicine spending growth
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
4 Things to know about the IQVIA 2018 and Beyond: Outlook and Turning Points report
Drug Cost
Lets Talk About Cost
4 Things to know about the IQVIA 2018 and Beyond: Outlook and Turning Points report
4 Things to know about the IQVIA 2018 and Beyond: Outlook and Turning Points report